Kenvue Inc. (NYSE:KVUE) Stake Trimmed by American Century Companies Inc.

American Century Companies Inc. trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,867,138 shares of the company's stock after selling 2,124,050 shares during the quarter. American Century Companies Inc. owned approximately 0.98% of Kenvue worth $402,813,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. FMR LLC increased its position in Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company's stock valued at $3,189,985,000 after buying an additional 3,075,019 shares in the last quarter. State Street Corp grew its holdings in Kenvue by 16.8% during the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares during the period. Geode Capital Management LLC grew its position in Kenvue by 0.9% during the third quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company's stock valued at $1,029,810,000 after buying an additional 399,846 shares during the period. Harris Associates L P grew its holdings in Kenvue by 7.5% in the third quarter. Harris Associates L P now owns 31,459,511 shares of the company's stock valued at $727,658,000 after purchasing an additional 2,186,114 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Kenvue by 2.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company's stock valued at $533,169,000 after acquiring an additional 561,570 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Kenvue Trading Up 1.3 %

KVUE stock traded up $0.30 during trading on Wednesday, reaching $23.40. 9,473,416 shares of the stock traded hands, compared to its average volume of 16,145,037. The firm has a market capitalization of $44.72 billion, a PE ratio of 44.15, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The business's 50 day moving average price is $22.17 and its 200-day moving average price is $22.44.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is 154.72%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on KVUE shares. UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday, January 15th. Canaccord Genuity Group upped their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Royal Bank of Canada reissued a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and cut their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.